CAR T Cells Impact the Treatment Landscape Across Hematologic Malignancies

Mohamad Mohty, MD, PhD, a professor of hematology at Saint-Antoine Hospital and University Pierre & Marie Curie, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.

Efficacy and safety data have been seen in a number of areas, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma (NHL), and multiple myeloma. Mohty says the results are becoming more consolidated with very recent follow-up and promising survival curves.